© Reuters. FILE PHOTO: A man stands on an overpass with an electronic board showing Shanghai and Shenzhen stock indexes in Shanghai BEIJING (Reuters) – China’s top banking and insurance regulator expressed
— BLA submission targeted in 2024 — — Alignment on clinical development and CMC requirements from recent interactions with FDA — — Two global Phase 3 trials expected to enroll 900 patients
96% vaccine efficacy against original COVID-19 in UK Phase 3 trial Vaccine cross-protection demonstrated against both variants circulating in the UK and South Africa Full enrollment (~30,000 participants) in PREVENT-19 Phase 3
25 February 2021 Company Announcements Office Australian Securities Exchange Limited Level 6, 20 Bridge Street Sydney NSW 2000 PRIME MEDIA GROUP LIMITED (ASX: PRT) Attached is an Appendix 4D and Financial Report
Company Plans to Meet with FDA in Q1 to Discuss Results of GALACTIC-HF Enrollment Completed in Cohort 2 of REDWOOD-HCM; Results Expected Mid-Year Company Provides 2021 Financial Guidance; More Than Two Years
MARGENZA™ approved in December 2020; commercial launch expected March 2021 July 2021 PDUFA target action dates for partnered products retifanlimab and teplizumab Multiple clinical updates across portfolio anticipated in 2021 Conference call
© Reuters. FILE PHOTO: Canary Wharf stands in London By Huw Jones LONDON (Reuters) – Britain is conducting a review of its financial rulebooks and policies to see how it can keep